Medtronic plc Logo

Medtronic plc

2M6.DE

(2.2)
Stock Price

82,39 EUR

10.95% ROA

7.8% ROE

28.98x PER

Market Cap.

112.833.995.507,90 EUR

58.12% DER

3.11% Yield

12.05% NPM

Medtronic plc Stock Analysis

Medtronic plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medtronic plc Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a low debt to equity ratio (44%), which means it has a small amount of debt compared to the ownership it holds

3 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

4 ROE

ROE in an average range (6.98%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 PBV

The stock's PBV ratio (1.89x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (629) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Medtronic plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medtronic plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Medtronic plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medtronic plc Revenue
Year Revenue Growth
1985 402.800.000
1986 502.000.000 19.76%
1987 653.300.000 23.16%
1988 741.700.000 11.92%
1989 836.600.000 11.34%
1990 1.021.400.000 18.09%
1991 1.176.900.000 13.21%
1992 1.328.200.000 11.39%
1993 1.390.900.000 4.51%
1994 1.742.400.000 20.17%
1995 2.169.100.000 19.67%
1996 2.438.200.000 11.04%
1997 2.604.800.000 6.4%
1998 4.134.100.000 36.99%
1999 5.014.600.000 17.56%
2000 5.551.800.000 9.68%
2001 6.410.800.000 13.4%
2002 7.665.200.000 16.36%
2003 9.087.200.000 15.65%
2004 10.054.600.000 9.62%
2005 11.292.000.000 10.96%
2006 12.299.000.000 8.19%
2007 13.515.000.000 9%
2008 14.599.000.000 7.43%
2009 15.817.000.000 7.7%
2010 15.933.000.000 0.73%
2011 16.184.000.000 1.55%
2012 16.590.000.000 2.45%
2013 17.005.000.000 2.44%
2014 20.261.000.000 16.07%
2015 28.833.000.000 29.73%
2016 29.710.000.000 2.95%
2017 29.953.000.000 0.81%
2018 30.557.000.000 1.98%
2019 28.913.000.000 -5.69%
2020 30.117.000.000 4%
2021 31.686.000.000 4.95%
2022 31.227.000.000 -1.47%
2023 31.936.000.000 2.22%
2023 32.364.000.000 1.32%
2024 31.660.000.000 -2.22%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medtronic plc Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 156.300.000 100%
1994 191.400.000 18.34%
1995 236.700.000 19.14%
1996 280.200.000 15.52%
1997 297.200.000 5.72%
1998 429.200.000 30.75%
1999 479.700.000 10.53%
2000 577.600.000 16.95%
2001 646.300.000 10.63%
2002 749.400.000 13.76%
2003 851.500.000 11.99%
2004 951.300.000 10.49%
2005 1.112.900.000 14.52%
2006 1.239.000.000 10.18%
2007 1.275.000.000 2.82%
2008 1.355.000.000 5.9%
2009 1.483.000.000 8.63%
2010 1.508.000.000 1.66%
2011 1.490.000.000 -1.21%
2012 1.557.000.000 4.3%
2013 1.477.000.000 -5.42%
2014 1.640.000.000 9.94%
2015 2.224.000.000 26.26%
2016 2.193.000.000 -1.41%
2017 2.253.000.000 2.66%
2018 2.330.000.000 3.3%
2019 2.331.000.000 0.04%
2020 2.493.000.000 6.5%
2021 2.746.000.000 9.21%
2022 2.696.000.000 -1.85%
2023 2.792.000.000 3.44%
2023 2.735.000.000 -2.08%
2024 2.704.000.000 -1.15%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medtronic plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 185.700.000
1986 227.100.000 18.23%
1987 313.200.000 27.49%
1988 373.000.000 16.03%
1989 399.800.000 6.7%
1990 483.300.000 17.28%
1991 549.100.000 11.98%
1992 613.000.000 10.42%
1993 470.300.000 -30.34%
1994 574.600.000 18.15%
1995 695.600.000 17.4%
1996 763.300.000 8.87%
1997 757.600.000 -0.75%
1998 1.280.100.000 40.82%
1999 1.587.900.000 19.38%
2000 1.685.200.000 5.77%
2001 1.962.800.000 14.14%
2002 2.371.900.000 17.25%
2003 2.801.400.000 15.33%
2004 3.213.600.000 12.83%
2005 3.659.400.000 12.18%
2006 4.153.000.000 11.89%
2007 4.707.000.000 11.77%
2008 5.152.000.000 8.64%
2009 5.789.000.000 11%
2010 5.533.000.000 -4.63%
2011 5.623.000.000 1.6%
2012 5.698.000.000 1.32%
2013 5.847.000.000 2.55%
2014 6.904.000.000 15.31%
2015 9.469.000.000 27.09%
2016 9.711.000.000 2.49%
2017 9.974.000.000 2.64%
2018 10.418.000.000 4.26%
2019 10.109.000.000 -3.06%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medtronic plc EBITDA
Year EBITDA Growth
1985 80.100.000
1986 125.100.000 35.97%
1987 152.400.000 17.91%
1988 145.300.000 -4.89%
1989 199.400.000 27.13%
1990 249.300.000 20.02%
1991 295.100.000 15.52%
1992 335.900.000 12.15%
1993 388.900.000 13.63%
1994 528.000.000 26.34%
1995 729.700.000 27.64%
1996 867.400.000 15.88%
1997 1.186.700.000 26.91%
1998 2.006.300.000 40.85%
1999 1.884.500.000 -6.46%
2000 2.578.900.000 26.93%
2001 3.097.000.000 16.73%
2002 3.366.800.000 8.01%
2003 4.011.300.000 16.07%
2004 4.851.500.000 17.32%
2005 4.878.500.000 0.55%
2006 4.700.000.000 -3.8%
2007 6.035.000.000 22.12%
2008 5.065.000.000 -19.15%
2009 5.037.000.000 -0.56%
2010 6.763.000.000 25.52%
2011 5.258.000.000 -28.62%
2012 5.957.000.000 11.73%
2013 6.673.000.000 10.73%
2014 6.249.000.000 -6.79%
2015 9.211.000.000 32.16%
2016 9.596.000.000 4.01%
2017 9.384.000.000 -2.26%
2018 9.664.000.000 2.9%
2019 8.241.000.000 -17.27%
2020 7.933.000.000 -3.88%
2021 8.932.000.000 11.18%
2022 9.042.000.000 1.22%
2023 9.080.000.000 0.42%
2023 8.578.000.000 -5.85%
2024 8.900.000.000 3.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medtronic plc Gross Profit
Year Gross Profit Growth
1985 285.300.000
1986 359.200.000 20.57%
1987 472.300.000 23.95%
1988 547.300.000 13.7%
1989 604.200.000 9.42%
1990 736.200.000 17.93%
1991 854.500.000 13.84%
1992 977.700.000 12.6%
1993 1.037.800.000 5.79%
1994 1.308.800.000 20.71%
1995 1.691.200.000 22.61%
1996 1.944.900.000 13.04%
1997 2.072.000.000 6.13%
1998 3.244.400.000 36.14%
1999 3.938.300.000 17.62%
2000 4.438.500.000 11.27%
2001 4.758.100.000 6.72%
2002 5.774.900.000 17.61%
2003 6.834.300.000 15.5%
2004 7.608.200.000 10.17%
2005 8.476.700.000 10.25%
2006 9.131.000.000 7.17%
2007 10.069.000.000 9.32%
2008 11.081.000.000 9.13%
2009 12.005.000.000 7.7%
2010 12.021.000.000 0.13%
2011 12.295.000.000 2.23%
2012 12.464.000.000 1.36%
2013 12.672.000.000 1.64%
2014 13.952.000.000 9.17%
2015 19.691.000.000 29.15%
2016 20.419.000.000 3.57%
2017 20.898.000.000 2.29%
2018 21.402.000.000 2.35%
2019 19.489.000.000 -9.82%
2020 19.634.000.000 0.74%
2021 21.541.000.000 8.85%
2022 20.508.000.000 -5.04%
2023 20.892.000.000 1.84%
2023 21.148.000.000 1.21%
2024 20.616.000.000 -2.58%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medtronic plc Net Profit
Year Net Profit Growth
1985 53.400.000
1986 73.800.000 27.64%
1987 86.500.000 14.68%
1988 97.400.000 11.19%
1989 108.700.000 10.4%
1990 133.400.000 18.52%
1991 161.500.000 17.4%
1992 197.200.000 18.1%
1993 232.400.000 15.15%
1994 294.000.000 20.95%
1995 437.800.000 32.85%
1996 530.000.000 17.4%
1997 457.400.000 -15.87%
1998 468.400.000 2.35%
1999 1.098.500.000 57.36%
2000 1.046.000.000 -5.02%
2001 984.000.000 -6.3%
2002 1.599.800.000 38.49%
2003 1.959.300.000 18.35%
2004 1.803.900.000 -8.61%
2005 2.546.700.000 29.17%
2006 2.802.000.000 9.11%
2007 2.231.000.000 -25.59%
2008 2.169.000.000 -2.86%
2009 3.099.000.000 30.01%
2010 3.096.000.000 -0.1%
2011 3.617.000.000 14.4%
2012 3.467.000.000 -4.33%
2013 3.065.000.000 -13.12%
2014 2.675.000.000 -14.58%
2015 3.538.000.000 24.39%
2016 4.028.000.000 12.16%
2017 3.104.000.000 -29.77%
2018 4.631.000.000 32.97%
2019 4.789.000.000 3.3%
2020 3.606.000.000 -32.81%
2021 5.039.000.000 28.44%
2022 3.758.000.000 -34.09%
2023 3.636.000.000 -3.36%
2023 3.676.000.000 1.09%
2024 4.168.000.000 11.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medtronic plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 1 0%
1997 1 0%
1998 0 0%
1999 1 0%
2000 1 0%
2001 1 0%
2002 1 100%
2003 2 0%
2004 1 0%
2005 2 50%
2006 2 0%
2007 2 -100%
2008 2 0%
2009 3 50%
2010 3 0%
2011 3 33.33%
2012 3 0%
2013 3 0%
2014 2 -50%
2015 3 0%
2016 3 0%
2017 2 0%
2018 3 33.33%
2019 4 0%
2020 3 -50%
2021 4 33.33%
2022 3 -50%
2023 3 0%
2023 3 0%
2024 3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medtronic plc Free Cashflow
Year Free Cashflow Growth
1989 51.500.000
1990 60.800.000 15.3%
1991 74.200.000 18.06%
1992 214.400.000 65.39%
1993 296.100.000 27.59%
1994 290.300.000 -2%
1995 336.700.000 13.78%
1996 273.400.000 -23.15%
1997 441.900.000 38.13%
1998 -788.500.000 156.04%
1999 699.900.000 212.66%
2000 1.391.800.000 49.71%
2001 1.203.800.000 -15.62%
2002 1.697.800.000 29.1%
2003 2.421.200.000 29.88%
2004 2.367.400.000 -2.27%
2005 963.200.000 -145.78%
2006 2.285.000.000 57.85%
2007 2.883.000.000 20.74%
2008 3.215.000.000 10.33%
2009 3.496.000.000 8.04%
2010 3.193.000.000 -9.49%
2011 3.853.000.000 17.13%
2012 4.426.000.000 12.95%
2013 4.563.000.000 3%
2014 4.331.000.000 -5.36%
2015 4.172.000.000 -3.81%
2016 5.626.000.000 25.84%
2017 3.616.000.000 -55.59%
2018 5.873.000.000 38.43%
2019 6.021.000.000 2.46%
2020 4.885.000.000 -23.25%
2021 5.978.000.000 18.28%
2022 4.580.000.000 -30.52%
2023 5.200.000.000 11.92%
2023 200.000.000 -2500%
2024 466.000.000 57.08%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medtronic plc Operating Cashflow
Year Operating Cashflow Growth
1989 106.800.000
1990 126.600.000 15.64%
1991 151.400.000 16.38%
1992 291.500.000 48.06%
1993 356.900.000 18.32%
1994 387.200.000 7.83%
1995 500.500.000 22.64%
1996 463.600.000 -7.96%
1997 590.100.000 21.44%
1998 455.300.000 -29.61%
1999 1.042.000.000 56.31%
2000 1.831.500.000 43.11%
2001 1.590.200.000 -15.17%
2002 2.078.200.000 23.48%
2003 2.845.800.000 26.97%
2004 2.819.400.000 -0.94%
2005 2.207.400.000 -27.72%
2006 2.979.000.000 25.9%
2007 3.489.000.000 14.62%
2008 3.878.000.000 10.03%
2009 4.131.000.000 6.12%
2010 3.741.000.000 -10.43%
2011 4.381.000.000 14.61%
2012 4.883.000.000 10.28%
2013 4.959.000.000 1.53%
2014 4.902.000.000 -1.16%
2015 5.218.000.000 6.06%
2016 6.880.000.000 24.16%
2017 4.684.000.000 -46.88%
2018 7.007.000.000 33.15%
2019 7.234.000.000 3.14%
2020 6.240.000.000 -15.93%
2021 7.346.000.000 15.06%
2022 6.039.000.000 -21.64%
2023 6.787.000.000 11.02%
2023 661.000.000 -926.78%
2024 986.000.000 32.96%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medtronic plc Capital Expenditure
Year Capital Expenditure Growth
1989 55.300.000
1990 65.800.000 15.96%
1991 77.200.000 14.77%
1992 77.100.000 -0.13%
1993 60.800.000 -26.81%
1994 96.900.000 37.25%
1995 163.800.000 40.84%
1996 190.200.000 13.88%
1997 148.200.000 -28.34%
1998 1.243.800.000 88.08%
1999 342.100.000 -263.58%
2000 439.700.000 22.2%
2001 386.400.000 -13.79%
2002 380.400.000 -1.58%
2003 424.600.000 10.41%
2004 452.000.000 6.06%
2005 1.244.200.000 63.67%
2006 694.000.000 -79.28%
2007 606.000.000 -14.52%
2008 663.000.000 8.6%
2009 635.000.000 -4.41%
2010 548.000.000 -15.88%
2011 528.000.000 -3.79%
2012 457.000.000 -15.54%
2013 396.000.000 -15.4%
2014 571.000.000 30.65%
2015 1.046.000.000 45.41%
2016 1.254.000.000 16.59%
2017 1.068.000.000 -17.42%
2018 1.134.000.000 5.82%
2019 1.213.000.000 6.51%
2020 1.355.000.000 10.48%
2021 1.368.000.000 0.95%
2022 1.459.000.000 6.24%
2023 1.587.000.000 8.07%
2023 461.000.000 -244.25%
2024 520.000.000 11.35%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medtronic plc Equity
Year Equity Growth
1985 348.700.000
1986 387.000.000 9.9%
1987 395.900.000 2.25%
1988 473.600.000 16.41%
1989 541.000.000 12.46%
1990 683.200.000 20.81%
1991 796.500.000 14.22%
1992 841.500.000 5.35%
1993 1.053.500.000 20.12%
1994 1.335.000.000 21.09%
1995 1.789.300.000 25.39%
1996 1.746.200.000 -2.47%
1997 2.044.200.000 14.58%
1998 3.654.600.000 44.07%
1999 4.491.500.000 18.63%
2000 5.509.500.000 18.48%
2001 6.431.100.000 14.33%
2002 7.906.400.000 18.66%
2003 9.077.000.000 12.9%
2004 10.449.500.000 13.13%
2005 9.382.500.000 -11.37%
2006 10.977.000.000 14.53%
2007 11.536.000.000 4.85%
2008 12.851.000.000 10.23%
2009 14.629.000.000 12.15%
2010 15.968.000.000 8.39%
2011 17.113.000.000 6.69%
2012 18.671.000.000 8.34%
2013 19.443.000.000 3.97%
2014 53.230.000.000 63.47%
2015 51.828.000.000 -2.71%
2016 50.416.000.000 -2.8%
2017 50.822.000.000 0.8%
2018 50.212.000.000 -1.21%
2019 50.872.000.000 1.3%
2020 51.602.000.000 1.41%
2021 52.722.000.000 2.12%
2022 51.665.000.000 -2.05%
2023 50.420.000.000 -2.47%
2023 51.647.000.000 2.38%
2024 48.160.000.000 -7.24%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medtronic plc Assets
Year Assets Growth
1985 527.400.000
1986 559.700.000 5.77%
1987 640.800.000 12.66%
1988 759.600.000 15.64%
1989 856.500.000 11.31%
1990 1.024.100.000 16.37%
1991 1.163.500.000 11.98%
1992 1.286.500.000 9.56%
1993 1.623.300.000 20.75%
1994 1.946.700.000 16.61%
1995 2.503.300.000 22.23%
1996 2.409.200.000 -3.91%
1997 2.774.700.000 13.17%
1998 4.870.300.000 43.03%
1999 5.669.400.000 14.09%
2000 7.038.900.000 19.46%
2001 10.904.500.000 35.45%
2002 12.320.800.000 11.5%
2003 14.110.800.000 12.69%
2004 16.617.400.000 15.08%
2005 19.664.800.000 15.5%
2006 19.512.000.000 -0.78%
2007 22.198.000.000 12.1%
2008 23.661.000.000 6.18%
2009 28.090.000.000 15.77%
2010 30.424.000.000 7.67%
2011 33.083.000.000 8.04%
2012 34.794.000.000 4.92%
2013 37.943.000.000 8.3%
2014 106.685.000.000 64.43%
2015 99.547.000.000 -7.17%
2016 99.816.000.000 0.27%
2017 91.393.000.000 -9.22%
2018 89.694.000.000 -1.89%
2019 90.689.000.000 1.1%
2020 93.083.000.000 2.57%
2021 90.981.000.000 -2.31%
2022 90.948.000.000 -0.04%
2023 89.981.000.000 -1.07%
2023 90.087.000.000 0.12%
2024 89.749.000.000 -0.38%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medtronic plc Liabilities
Year Liabilities Growth
1985 178.700.000
1986 172.700.000 -3.47%
1987 244.900.000 29.48%
1988 286.000.000 14.37%
1989 315.500.000 9.35%
1990 340.900.000 7.45%
1991 367.000.000 7.11%
1992 445.000.000 17.53%
1993 569.800.000 21.9%
1994 611.700.000 6.85%
1995 714.000.000 14.33%
1996 663.000.000 -7.69%
1997 730.500.000 9.24%
1998 1.215.700.000 39.91%
1999 1.177.900.000 -3.21%
2000 1.529.400.000 22.98%
2001 4.473.400.000 65.81%
2002 4.414.400.000 -1.34%
2003 5.033.800.000 12.3%
2004 6.167.900.000 18.39%
2005 10.282.300.000 40.01%
2006 8.535.000.000 -20.47%
2007 10.662.000.000 19.95%
2008 10.810.000.000 1.37%
2009 13.461.000.000 19.69%
2010 14.456.000.000 6.88%
2011 15.970.000.000 9.48%
2012 16.123.000.000 0.95%
2013 18.500.000.000 12.85%
2014 53.455.000.000 65.39%
2015 47.719.000.000 -12.02%
2016 49.400.000.000 3.4%
2017 40.571.000.000 -21.76%
2018 39.482.000.000 -2.76%
2019 39.817.000.000 0.84%
2020 41.481.000.000 4.01%
2021 38.259.000.000 -8.42%
2022 39.283.000.000 2.61%
2023 39.561.000.000 0.7%
2023 38.440.000.000 -2.92%
2024 41.589.000.000 7.57%

Medtronic plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
25.19
Net Income per Share
3.04
Price to Earning Ratio
28.98x
Price To Sales Ratio
3.46x
POCF Ratio
16.5
PFCF Ratio
21.93
Price to Book Ratio
2.37
EV to Sales
4.28
EV Over EBITDA
16.04
EV to Operating CashFlow
20.21
EV to FreeCashFlow
27.09
Earnings Yield
0.03
FreeCashFlow Yield
0.05
Market Cap
112,83 Bil.
Enterprise Value
139,39 Bil.
Graham Number
50.33
Graham NetNet
-20.51

Income Statement Metrics

Net Income per Share
3.04
Income Quality
1.74
ROE
0.08
Return On Assets
0.04
Return On Capital Employed
0.06
Net Income per EBT
0.8
EBT Per Ebit
0.95
Ebit per Revenue
0.16
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.65
Operating Profit Margin
0.16
Pretax Profit Margin
0.15
Net Profit Margin
0.12

Dividends

Dividend Yield
0.03
Dividend Yield %
3.11
Payout Ratio
0.93
Dividend Per Share
2.73

Operating Metrics

Operating Cashflow per Share
5.33
Free CashFlow per Share
3.98
Capex to Operating CashFlow
0.25
Capex to Revenue
0.05
Capex to Depreciation
0.66
Return on Invested Capital
0.05
Return on Tangible Assets
0.11
Days Sales Outstanding
67.35
Days Payables Outstanding
73.69
Days of Inventory on Hand
174.14
Receivables Turnover
5.42
Payables Turnover
4.95
Inventory Turnover
2.1
Capex per Share
1.36

Balance Sheet

Cash per Share
6,06
Book Value per Share
37,24
Tangible Book Value per Share
-4.44
Shareholders Equity per Share
37.07
Interest Debt per Share
22.12
Debt to Equity
0.58
Debt to Assets
0.31
Net Debt to EBITDA
3.06
Current Ratio
2.13
Tangible Asset Value
-5,74 Bil.
Net Current Asset Value
-19,64 Bil.
Invested Capital
71843000000
Working Capital
11,66 Bil.
Intangibles to Total Assets
0.6
Average Receivables
6,07 Bil.
Average Payables
2,35 Bil.
Average Inventory
5315500000
Debt to Market Cap
0.25

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medtronic plc Dividends
Year Dividends Growth
2008 1
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 100%
2013 0 0%
2014 1 100%
2015 1 0%
2016 2 0%
2017 1 0%
2018 2 100%
2019 2 50%
2020 2 0%
2021 2 0%
2022 3 0%
2023 3 0%
2024 2 0%

Medtronic plc Profile

About Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

CEO
Mr. Geoffrey Straub Martha
Employee
95.000
Address
20 On Hatch
Dublin, 2

Medtronic plc Executives & BODs

Medtronic plc Executives & BODs
# Name Age
1 Dr. Laura Mauri M.D., M.Sc.
Senior Vice President and Chief Scientific & Medical Officer
70
2 Mr. Ryan Weispfenning
Vice President & Head of Investor Relations
70
3 Gary Corona
Senior Vice President of Global Financial Planning and Analysis & Interim Chief Financial Officer
70
4 Dr. Kenneth E. Washington Ph.D.
Senior Vice President and Chief Technology & Innovation Officer
70
5 Mr. Gregory L. Smith
Executive Vice President of Global Operations & Supply Chain
70
6 Ms. Jennifer M. Kirk
Senior Vice President, Global Controller & Chief Accounting Officer
70
7 Mr. Mark Ploof
Senior Vice President of Global Operations and Business Services
70
8 Mr. Geoffrey Straub Martha
Chairman of the Board & Chief Executive Officer
70
9 Mr. Sean M. Salmon
Executive Vice President & President of Cardiovascular Portfolio
70
10 Mr. Brett A. Wall
Executive Vice President & President of Neuroscience Portfolio
70

Medtronic plc Competitors

Visa Inc. Logo
Visa Inc.

3V64.DE

(3.0)
Novo Nordisk A/S Logo
Novo Nordisk A/S

NOVC.DE

(4.5)
Johnson & Johnson Logo
Johnson & Johnson

JNJ.DE

(2.2)
Cisco Systems, Inc. Logo
Cisco Systems, Inc.

CIS.DE

(3.2)